H1 sales growth for Novo Nordisk’s segment that includes Ozempic and Wegovy was down from the same period in 2024.

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

Discover how weight loss medications and smart nutrition can silence cravings in Food Noise by Dr. Jack Mosley.

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Chief financial officer Karsten Munk Knudsen said that the pharma giant's cash channel was key to regaining market share and ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The pharmaceutical giant has witnessed significant revenue boosts from its ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.